Dr. Radhakrishnan Ramchandren, MD
NPI: 1700089331
Total Payments
$268,424
2024 Payments
$67,956
Companies
63
Transactions
500
Medicare Patients
635
Medicare Billing
$142,451
Payment Breakdown by Category
Consulting$117,526 (43.8%)
Other$95,825 (35.7%)
Travel$40,054 (14.9%)
Food & Beverage$10,915 (4.1%)
Research$4,090 (1.5%)
Education$13.64 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $117,526 | 43 | 43.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $87,387 | 26 | 32.6% |
| Travel and Lodging | $40,054 | 77 | 14.9% |
| Food and Beverage | $10,915 | 343 | 4.1% |
| Honoraria | $8,438 | 3 | 3.1% |
| Unspecified | $4,090 | 5 | 1.5% |
| Education | $13.64 | 3 | 0.0% |
Payments by Type
General
$264,334
495 transactions
Research
$4,090
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $53,300 | 33 | $0 (2024) |
| Seagen Inc. | $32,671 | 41 | $0 (2023) |
| Merck Sharp & Dohme LLC | $28,056 | 31 | $0 (2023) |
| Celgene Corporation | $23,004 | 37 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $21,902 | 24 | $0 (2024) |
| Seattle Genetics, Inc. | $19,007 | 38 | $0 (2019) |
| ADC Therapeutics America, Inc. | $12,245 | 12 | $0 (2023) |
| PFIZER INC. | $10,586 | 23 | $0 (2024) |
| Sandoz Inc. | $9,541 | 8 | $0 (2018) |
| SOBI, INC | $9,353 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $67,956 | 67 | GlaxoSmithKline, LLC. ($51,106) |
| 2023 | $43,731 | 118 | Merck Sharp & Dohme LLC ($12,319) |
| 2022 | $27,096 | 80 | Seagen Inc. ($12,568) |
| 2021 | $9,489 | 34 | Seagen Inc. ($3,460) |
| 2020 | $28,226 | 45 | Celgene Corporation ($12,479) |
| 2019 | $20,200 | 57 | Celgene Corporation ($10,175) |
| 2018 | $43,871 | 50 | E.R. Squibb & Sons, L.L.C. ($11,937) |
| 2017 | $27,855 | 49 | Seattle Genetics, Inc. ($9,663) |
All Payment Transactions
500 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | Cash or cash equivalent | $175.54 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $103.07 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/08/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: ADCETRIS CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | Cash or cash equivalent | $105.97 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | In-kind items and services | $415.90 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $123.50 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | In-kind items and services | $1,206.50 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | In-kind items and services | $301.61 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | In-kind items and services | $1,276.05 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $64.16 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2024 | PFIZER INC. | TRAZIMERA | — | In-kind items and services | $940.00 | Research |
| Study: NIROGACESTAT CLINICAL PUBLICATION PROGRAM | ||||||
| 09/19/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: CELLT | ||||||
| 08/01/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $330.00 | Research |
| Study: BRENTUXIMAB VEDOTIN CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 07/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $16.98 | General |
| 06/21/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $17.23 | General |
| Category: ONCOLOGY | ||||||
| 06/18/2024 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: ONCOLOGY | ||||||
| 06/17/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.27 | General |
| Category: Oncology | ||||||
| 06/12/2024 | SOBI, INC | VONJO (Drug) | Consulting Fee | Cash or cash equivalent | $4,625.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TRILLIUM CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,880 | 2 |
| ADCETRIS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| NIROGACESTAT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| BRENTUXIMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 183 | 563 | $172,905 | $45,816 |
| 2022 | 5 | 172 | 407 | $105,360 | $33,737 |
| 2021 | 5 | 159 | 415 | $106,985 | $35,247 |
| 2020 | 4 | 121 | 335 | $89,405 | $27,651 |
Total Patients
635
Total Services
1,720
Medicare Billing
$142,451
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 101 | 346 | $104,100 | $23,504 | 22.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 28 | 147 | $35,280 | $13,202 | 37.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 39 | 55 | $25,850 | $7,120 | 27.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 15 | 15 | $7,675 | $1,990 | 25.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 84 | 216 | $42,230 | $14,338 | 34.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 111 | $33,855 | $8,640 | 25.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 34 | 46 | $17,795 | $6,936 | 39.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 19 | 19 | $7,505 | $2,260 | 30.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 15 | 15 | $3,975 | $1,564 | 39.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 71 | 221 | $43,095 | $15,619 | 36.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 22 | 121 | $36,905 | $9,459 | 25.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 35 | 42 | $16,170 | $6,172 | 38.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 20 | 20 | $7,900 | $2,773 | 35.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 11 | 11 | $2,915 | $1,224 | 42.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 43 | 173 | $33,735 | $9,906 | 29.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 35 | 49 | $18,865 | $7,603 | 40.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 17 | 87 | $26,535 | $6,983 | 26.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 26 | 26 | $10,270 | $3,159 | 30.8% |
About Dr. Radhakrishnan Ramchandren, MD
Dr. Radhakrishnan Ramchandren, MD is a Independent Medical Examiner healthcare provider based in West Reading, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2007. The National Provider Identifier (NPI) number assigned to this provider is 1700089331.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Radhakrishnan Ramchandren, MD has received a total of $268,424 in payments from pharmaceutical and medical device companies, with $67,956 received in 2024. These payments were reported across 500 transactions from 63 companies. The most common payment nature is "Consulting Fee" ($117,526).
As a Medicare-enrolled provider, Ramchandren has provided services to 635 Medicare beneficiaries, totaling 1,720 services with total Medicare billing of $142,451. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Independent Medical Examiner
- Other Specialties Internal Medicine, Hematology & Oncology
- Location West Reading, PA
- Active Since 06/10/2007
- Last Updated 04/09/2025
- Taxonomy Code 202C00000X
- Entity Type Individual
- NPI Number 1700089331
Products in Payments
- OJJAARA (Drug) $53,106
- ADCETRIS (Biological) $45,841
- OPDIVO (Biological) $18,162
- Revlimid (Drug) $16,889
- VONJO (Drug) $9,353
- IMBRUVICA (Drug) $8,359
- VYNDAQEL (Drug) $5,634
- Rituxan (Biological) $4,933
- SGN35 (Biological) $4,462
- CALQUENCE (Drug) $4,346
- Imbruvica (Drug) $3,695
- VYXEOS (Drug) $3,354
- JCAR017 (Drug) $2,825
- Tazverik (Drug) $2,775
- Zydelig (Drug) $2,148
- XPOVIO (Drug) $1,977
- VENCLEXTA (Biological) $1,320
- Non-Covered Product (Drug) $620.01
- KEYTRUDA (Biological) $298.44
- REBLOZYL (Biological) $188.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.